Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $1.77.
Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Gamida Cell, and Geron. According to TipRanks, Blum has an average return of -24.4% and a 27.32% success rate on recommended stocks.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $11.00, which is a 521.47% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $5.92 and a one-year low of $1.60. Currently, Autolus Therapeutics has an average volume of 395.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
- Autolus Therapeutics 75M share Spot Secondary priced at $2.00
- Autolus Tanks After Pricing of Public Offering
- Autolus Announces Pricing of Public Offering
- Autolus Therapeutics to receive two $35M payments from Blackstone Life Sciences
